share_log

ALLARITY THERAPEUTICS INC | 8-K: Current report

SEC announcement ·  Mar 8 08:40
Summary by Moomoo AI
On March 8, 2024, Allarity Therapeutics, Inc., a clinical-stage biopharmaceutical company, announced its financial results for the fiscal year ended December 31, 2023, and provided a business update. The company reported a 50% reduction in net loss from operations, down to $17.1 million from the previous year's $34 million, and a 26% reduction in net loss, which stood at $11.9 million. Allarity also highlighted significant clinical benefits observed in a Phase 2 study of its lead drug, stenoparib, for advanced ovarian cancer, following a dosing protocol change. The study's early data showed a complete response in one patient and stable disease in four others. Allarity's interim CEO, Thomas Jensen, emphasized the company's progress in DRP-guided drug development and the potential of stenoparib. The company also announced leadership changes, including the appointment of Jensen as interim CEO and Jeremy Graff, Ph.D., as an Executive Advisor. Looking ahead, Allarity expects to release interim data from the ongoing Phase 2 clinical trial of stenoparib in the second quarter of 2024.
On March 8, 2024, Allarity Therapeutics, Inc., a clinical-stage biopharmaceutical company, announced its financial results for the fiscal year ended December 31, 2023, and provided a business update. The company reported a 50% reduction in net loss from operations, down to $17.1 million from the previous year's $34 million, and a 26% reduction in net loss, which stood at $11.9 million. Allarity also highlighted significant clinical benefits observed in a Phase 2 study of its lead drug, stenoparib, for advanced ovarian cancer, following a dosing protocol change. The study's early data showed a complete response in one patient and stable disease in four others. Allarity's interim CEO, Thomas Jensen, emphasized the company's progress in DRP-guided drug development and the potential of stenoparib. The company also announced leadership changes, including the appointment of Jensen as interim CEO and Jeremy Graff, Ph.D., as an Executive Advisor. Looking ahead, Allarity expects to release interim data from the ongoing Phase 2 clinical trial of stenoparib in the second quarter of 2024.
Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more